Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Tonix Pharmaceuticals revenue
Tonix Pharmaceuticals's revenue is $12.7 million.
What is Tonix Pharmaceuticals's revenue?
- Tonix Pharmaceuticals's revenue growth from 2023 to 2024 is 63.34%.
- Tonix Pharmaceuticals has 26 employees, and the revenue per employee ratio is $488,000.
- Tonix Pharmaceuticals's peak quarterly revenue was $4.0M in 2023(q3).
- Tonix Pharmaceuticals peak revenue was $12.7M in 2024.
- Tonix Pharmaceuticals annual revenue for 2024 was 12.7M, 63.34% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Tonix Pharmaceuticals financial information
| CEO | Seth Lederman |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 26 |
| Date Founded | 2007 |
| Headquarters | New York, New York |
| Number of Locations | 5 |
| Revenue | $12.7M |
| Net Income | -$110,218,000 |
| Gross Proft | $4.9M (2024) |
| PE Ratio | -0.27 |
| Tax Rate | -0.0% |
| Market Capitalization | $35.3M |
| Total Assets | $225,690,000 |
| Ticker | TNXP |
Tonix Pharmaceuticals jobs you might like
Tonix Pharmaceuticals financing
Tonix Pharmaceuticals received early financing of $1.6M on 2011-10-20.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Debt | $1.6M | 10/2011 |
| Post Ipo Debt | $710K | 11/2012 |
| Post Ipo Equity | $1M | 12/2012 |
| Post Ipo Equity | $43.5M | 01/2014 |
| Post Ipo Equity | $28.7M | 02/2015 |
| Post Ipo Equity | $20.1M | 07/2015 |
| Post Ipo Equity | $5.2M | 10/2016 |
| Post Ipo Equity | $8M | 03/2017 |
| Post Ipo Equity | $9M | 11/2019 |
| Post Ipo Equity | $40M | 01/2021 |
| Post Ipo Equity | $70M | 02/2021 |
Tonix Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Technology Partners | Post Ipo Equity |
| SABBY MANAGEMENT LLC | Post Ipo Equity |
| Broadfin Capital | Post Ipo Equity |
| Deerfield Management | Post Ipo Equity |
Tonix Pharmaceuticals competitors
Tonix Pharmaceuticals's top competitor, Sagent Pharmaceuticals, earned an annual revenue of $318.3M.
Tonix Pharmaceuticals's smallest competitor is GeoVax with revenue of $81.5K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Ligand Pharmaceuticals | - | $241.5M | 116 | - |
| Imprimis Pharmaceuticals | - | $48.9M | 143 | - |
| Geron | - | $77.0M | 15 | - |
| Acorda Therapeutics | - | $117.6M | 344 | - |
| GeoVax | - | $81,526 | 5 | - |
| GlobeImmune | - | $6.5M | 22 | - |
| Sagent Pharmaceuticals | - | $318.3M | 440 | - |
| Lineagen | - | $3.0M | 52 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Tonix Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Tonix Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Tonix Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Tonix Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Tonix Pharmaceuticals. The data presented on this page does not represent the view of Tonix Pharmaceuticals and its employees or that of Zippia.
Tonix Pharmaceuticals may also be known as or be related to Tonix Pharmaceuticals, Tonix Pharmaceuticals Holding Corp and Tonix Pharmaceuticals Holding Corp.